Hypertensive emergency

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

Retrieved on: 
Saturday, February 4, 2023
Gossamer, GOSS, Pomerantz, LLP, Patient, Merck, Clinical trial, Hypertensive emergency, PAH, News, Pharmaceutical industry

NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).

Key Points: 
  • NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

Retrieved on: 
Monday, January 23, 2023
Chairperson, Aerovent, Anthera Pharmaceuticals, Acquisition, Actelion, Veteran, Patient, Boston Scientific, Hypertensive emergency, PAH, Medtronic, Growth, Therapy, Viatris, Pharmaceutical industry

WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate’s Board of Directors.

Key Points: 
  • WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate’s Board of Directors.
  • With over 40 years of working in the industry, Mr. Santel brings to Aerovate extensive experience in building successful pharmaceutical companies.
  • "We are excited to welcome Don to Aerovate’s Board of Directors.
  • “The appointment of Mr. Santel further strengthens the breadth and depth of the Board’s capabilities, and we look forward to having Don on the Board as we support the company’s continued growth.”
    “I am thrilled to join the highly accomplished team of PAH veterans and cardiopulmonary experts at Aerovate,” said Mr. Santel.

Aerami Therapeutics to Present at Biotech Showcase™ 2023 during the 41st Annual J.P. Morgan Healthcare Conference Week

Retrieved on: 
Thursday, January 5, 2023
Conference, Vasodilation, PST, PAH, Biotechnology, Hypertensive emergency, Pharmaceutical industry

DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions, today announced senior leaders are scheduled to participate in the Biotech Showcase™ 2023, with a presentation scheduled for 2 PM (PST) on Monday, January 9, 2023, during the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco, California.

Key Points: 
  • DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions, today announced senior leaders are scheduled to participate in the Biotech Showcase™ 2023, with a presentation scheduled for 2 PM (PST) on Monday, January 9, 2023, during the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco, California.
  • At the conference, newly appointed CEO Lisa Yañez will share:
    Aerami’s plans to advance AER-901 (inhaled imatinib) into a Phase 2 trial during the first half of 2023.
  • Aerami’s approach to clinical development in pulmonary arterial hypertension (PAH), a rare and progressive disease with no cure and currently approved therapies primarily mediating vasodilation.
  • New developments and anticipated milestones related to Aerami’s pipeline and AER-901 development program.

Reviva Pharmaceuticals Announces Letter to Shareholders

Retrieved on: 
Wednesday, January 4, 2023
CYP3A4, Partnership, Central nervous system, Food, MDD, Bipolar disorder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hope, COVID-19, DDI, Inflammation, Serotonin, NDA, Risk, CNS, Patient, Idiopathic pulmonary fibrosis, Letter, Attention deficit hyperactivity disorder predominantly inattentive, ADHD, Safety, Investment, FDA, IPF, Schizophrenia, Drug, Quality of life, RP5063, PAH, Trial of the century, Liver, Hypertensive emergency, Pharmaceutical industry, Brilaroxazine

CUPERTINO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, is pleased to announce a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D.

Key Points: 
  • CUPERTINO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, is pleased to announce a letter to shareholders from Founder, President, and CEO, Laxminarayan Bhat, Ph.D.
  • It is with great pride and enthusiasm that I write this shareholder letter to you today.
  • This capital raise, led by a current institutional investor of Reviva, is an important milestone that we believe demonstrates a strong belief in our ability to deliver results.
  • On behalf of our deeply committed team and board of directors, I want to thank you, our shareholders, for your continued trust and support in our company.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

Retrieved on: 
Monday, January 2, 2023
Clinical trial, Pomerantz, News, Patient, LLP, GOSS, Gossamer, PAH, Merck, Hypertensive emergency, Pharmaceutical industry

NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).

Key Points: 
  • NEW YORK, Jan. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS

Retrieved on: 
Sunday, December 25, 2022
Clinical trial, Pomerantz, News, Patient, LLP, GOSS, Gossamer, PAH, Merck, Hypertensive emergency, Pharmaceutical industry

NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).

Key Points: 
  • NEW YORK, Dec. 24, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of Brilaroxazine

Retrieved on: 
Thursday, December 15, 2022
Drug, Depression, CYP3A4, ADHD, PAH, Positive and Negative Syndrome Scale, Serotonin, Central nervous system, IPF, MDD, Toxicology, Liver, Hypertensive emergency, Trial of the century, Inflammation, Attention deficit hyperactivity disorder predominantly inattentive, CNS, Food, FDA, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Schizoaffective disorder, Therapy, DDI, Bipolar disorder, Phenytoin, Cognition, Substance abuse, Pulmonary fibrosis, Polypharmacy, Patient, United, Nature, Cmax, PANSS, Schizophrenia, Drug Quality and Security Act, Itraconazole, NDA, Lipid, Risk, RP5063, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Brilaroxazine

CUPERTINO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced positive data from its recently completed clinical drug-drug interaction (DDI) study investigating the potential effect of CYP3A4 enzyme on brilaroxazine in healthy subjects. The CYP3A4 enzyme plays a pivotal role in helping the body metabolize and remove small foreign molecules and is primarily found in the liver and intestine. DDI evaluation is a critical clinical pharmacology study required by the U.S. Food and Drug Administration (FDA) and other regulatory agencies globally for approving a new drug to market. Brilaroxazine is a serotonin/dopamine modulator in late-stage clinical development for the treatment of schizophrenia.

Key Points: 

    Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)

    Retrieved on: 
    Monday, December 5, 2022
    Degenerative disease, Insulin, Software, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., PAH, Abbreviated New Drug Application, Lung, New York Heart Association Functional Classification, COVID-19, Hypertensive emergency, INSPIRE, Treprostinil, Health, Food, FDA, Safety, Regulation of tobacco by the U.S. Food and Drug Administration, Commercial, Douglas v. U.S. District Court ex rel Talk America, Intellectual property, Patent, Senior, Functional, Coronavirus, Pulmonary hypertension, NYHA, Trial of the century, Environment, Pharmacology, Exercise, District court, ANDA, Patient, Physician, Pump, Court, United Therapeutics, PTAB, NDA, Partnership, Medical device, Pharmaceutical industry, Novartis

    Mainbridge will perform all development, validation and testing activities required for the pump and related consumables.

    Key Points: 
    • Mainbridge will perform all development, validation and testing activities required for the pump and related consumables.
    • In connection with the execution of the Pump Agreement, Liquidia and Sandoz also agreed to extend their promotion agreement for Treprostinil Injection by another five years until December 31, 2032.
    • Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH).
    • Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection.

    Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH

    Retrieved on: 
    Tuesday, December 6, 2022
    Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Therapy, III, PAH, Subdural hematoma, University of Giessen, Pulmonary hypertension, Peripheral edema, Patient, Entrepreneurship, Diarrhea, University Hospital (Newark, New Jersey), FC, Nausea, HIV disease progression rates, GOSS, Vomiting, Bio, Week, Resistance wire, SAE, Framingham Risk Score, Inflammation, Pulmonary artery, Hypertensive emergency, Teaching hospital, N-terminal prohormone of brain natriuretic peptide, Pharmaceutical industry, Medical device, CSF1R, Gossamer, Medicine, PVR

    The Phase 2 TORREY study enrolled 86 patients with WHO Functional Class (FC) II or III PAH, with 42 randomized to the placebo arm and 44 randomized to the seralutinib arm.

    Key Points: 
    • The Phase 2 TORREY study enrolled 86 patients with WHO Functional Class (FC) II or III PAH, with 42 randomized to the placebo arm and 44 randomized to the seralutinib arm.
    • The primary endpoint of the study was change from baseline to Week 24 in pulmonary vascular resistance (PVR).
    • An observed mean difference in 6MWD between placebo and seralutinib of 6.5 meters numerically favored the seralutinib arm.
    • Changes in PVR favored seralutinib across all pre-specified patient sub-group analyses, demonstrating consistency in the hemodynamic outcomes observed in the study.

    A novel azapeptide editing method provides potential for new drug development, Feinstein Institutes research shows

    Retrieved on: 
    Monday, November 28, 2022
    Other Health, Research, General Health, Pharmaceutical, Oncology, Biometrics, Clinical Trials, Science, Biotechnology, AIDS, Other Science, Health, Mental health, Doctor of Philosophy, Science, Genetics, Hypertensive emergency, Peptide, HMGB1, Chemistry, Multimedia, Northwell Health, Enzyme, Feinstein Institute for Medical Research, Patient, Arthritis, Bradykinin, Protein, Inflammation, Autoimmunity, Medicine, Drug development, Nature Communications, Cancer, Medical research, Research, Therapy, Molecular medicine, Credit, Organic acid, HIV, Drug discovery, Fine chemical, Hospital, Atazanavir, MD

    Azapeptides are one type of peptide alternative that has shown great potential as therapeutics, exemplified by the HIV drug, Atazanavir (Reyataz).

    Key Points: 
    • Azapeptides are one type of peptide alternative that has shown great potential as therapeutics, exemplified by the HIV drug, Atazanavir (Reyataz).
    • View the full release here: https://www.businesswire.com/news/home/20221128005470/en/
      Dr. Yousef Al-Abed is co-director of the Institute of Bioelectrionic Medicine at the Feinstein Institutes for Medical Research.
    • A technology that circumvents these problems inherent to native peptides will change the future landscape of drug discovery, said Dr. Al-Abed.
    • The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State.